Rua Bioscience adds medicinal MDMA to its cannabis lineup as New Zealand opens prescribing

Rua Bioscience supplies regulated medicines from Tairāwhiti, New Zealand, starting with medical cannabis; PharmAla manufactures GMP-grade LaNeo MDMA in Toronto.

Rua's cannabis licences, quality systems and prescriber relationships transfer to psychedelics, opening a second regulated category with minimal new capital.

Rua built its business on the safe, compliant supply of controlled medicines, beginning with medical cannabis in Tairāwhiti, accumulating licences, quality systems, regulatory expertise and prescriber relationships. PharmAla, a self-described 'regulatory first' biotech, became one of the first companies to manufacture GMP-grade MDMA, supplying clinical trials and authorised prescribers internationally.

Australia allowed authorised-psychiatrist MDMA prescribing in 2023, and New Zealand approved psilocybin for treatment-resistant depression in 2025. On September 1, 2026, PharmAla terminated by mutual consent its exclusive New Zealand distribution deal with Veridion Group, which held no inventory or regulatory registrations and involved no payments. On October 8, 2026, Rua and PharmAla signed a distribution and licence agreement for Rua to import, distribute and sell LaNeo MDMA in New Zealand, with the first shipment on consignment.

New Zealand became only the second country after Australia to allow authorised psychiatrists to prescribe MDMA, creating a first-mover supply opening.

Rua's existing cannabis licensing, quality systems and prescriber relationships transfer to the new category at minimal incremental cost.

Consignment-based first supply removes upfront inventory risk while the market is unproven.

Psychedelic medicine is moving into mainstream clinical practice — NZ already allowed psilocybin for treatment-resistant depression in 2025.

A regulatory moat built in one controlled medicine is reusable infrastructure: entering the next category early and capital-light beats waiting for the market to mature.

As of the October 8, 2026 announcement, Rua was working with PharmAla and Medsafe to complete remaining regulatory and quality steps before the first shipment. Patient numbers are expected to be modest at first, and both companies frame the deal as a first step in a broader shift in how New Zealand approaches mental health treatment.